Literature DB >> 17921727

Active surveillance with selective radical treatment for localized prostate cancer.

Nicholas J van As1, Chris C Parker.   

Abstract

The challenge of managing localized prostate cancer is to distinguish patients with clinically relevant cancers, who may benefit from radical treatment, from the remainder who do not need any intervention. Active surveillance with selective radial intervention is a management strategy that offers patients the hope of avoiding "unnecessary" treatment without detriment to their long-term survival. Here we discuss the rationale for active surveillance, and the early results. There is no consensus on the optimum active surveillance protocol, with uncertainty regarding the interpretation of PSA kinetics, repeat biopsy results and prostate imaging. In the future, it is likely that molecular markers will revolutionize our ability to select patients who will benefit from definitive treatment. In the meantime, active surveillance provides an attractive way of reducing over treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17921727     DOI: 10.1097/PPO.0b013e318156ff65

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  12 in total

1.  Prostate cancer screening: Canadian guidelines 2011.

Authors:  Jonathan I Izawa; Laurence Klotz; D Robert Siemens; Wassim Kassouf; Alan So; John Jordan; Michael Chetner; Alla E Iansavichene
Journal:  Can Urol Assoc J       Date:  2011-08       Impact factor: 1.862

Review 2.  Active surveillance for favorable-risk prostate cancer: background, patient selection, triggers for intervention, and outcomes.

Authors:  Laurence Klotz
Journal:  Curr Urol Rep       Date:  2012-04       Impact factor: 3.092

Review 3.  Active surveillance for prostate cancer: a review.

Authors:  Laurence Klotz
Journal:  Curr Urol Rep       Date:  2010-05       Impact factor: 3.092

Review 4.  Benchmarks for success in focal therapy of prostate cancer: cure or control?

Authors:  Hashim U Ahmed; Mark Emberton
Journal:  World J Urol       Date:  2010-09-10       Impact factor: 4.226

5.  Active surveillance for prostate cancer: patient selection and management.

Authors:  L Klotz
Journal:  Curr Oncol       Date:  2010-09       Impact factor: 3.677

Review 6.  What is low-risk prostate cancer and what is its natural history?

Authors:  Helen O'Donnell; Chris Parker
Journal:  World J Urol       Date:  2008-06-21       Impact factor: 4.226

7.  The role of magnetic resonance imaging in delineating clinically significant prostate cancer.

Authors:  Karim Chamie; Geoffrey A Sonn; David S Finley; Nelly Tan; Daniel J A Margolis; Steven S Raman; Shyam Natarajan; Jiaoti Huang; Robert E Reiter
Journal:  Urology       Date:  2014-02       Impact factor: 2.649

8.  Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository.

Authors:  Lisa F Newcomb; James D Brooks; Peter R Carroll; Ziding Feng; Martin E Gleave; Peter S Nelson; Ian M Thompson; Daniel W Lin
Journal:  Urology       Date:  2009-09-16       Impact factor: 2.649

9.  Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.

Authors:  Freddie C Hamdy; Jenny L Donovan; J Athene Lane; Malcolm Mason; Chris Metcalfe; Peter Holding; Julia Wade; Sian Noble; Kirsty Garfield; Grace Young; Michael Davis; Tim J Peters; Emma L Turner; Richard M Martin; Jon Oxley; Mary Robinson; John Staffurth; Eleanor Walsh; Jane Blazeby; Richard Bryant; Prasad Bollina; James Catto; Andrew Doble; Alan Doherty; David Gillatt; Vincent Gnanapragasam; Owen Hughes; Roger Kockelbergh; Howard Kynaston; Alan Paul; Edgar Paez; Philip Powell; Stephen Prescott; Derek Rosario; Edward Rowe; David Neal
Journal:  Health Technol Assess       Date:  2020-08       Impact factor: 4.014

10.  High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series.

Authors:  H U Ahmed; E Zacharakis; T Dudderidge; J N Armitage; R Scott; J Calleary; R Illing; A Kirkham; A Freeman; C Ogden; C Allen; M Emberton
Journal:  Br J Cancer       Date:  2009-06-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.